DAV (Disabled American Veterans) has announced the launch of its new online diabetes resource page, developed in partnership with Dexcom, a global leader in glucose biosensing. The new resource page ...

Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...

Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...

If you are wondering whether DexCom's current share price lines up with its underlying worth, or if the market is mispricing the stock, this article walks through that question step by step. DexCom ...

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...

Add Yahoo as a preferred source to see more of our stories on Google. Dexcom recalled an Android app for its G6 continuous glucose monitor because of a problem with the app stopping unexpectedly.

Dexcom has experienced technical issues since Saturday morning, keeping parents from learning when a child with diabetes is experiencing dangerous blood sugar swings. Dexcom blamed the problem on a ...

“This small thing,” Nick Jonas says while holding the all-new Dexcom G7 Continuous Glucose Monitoring (CGM) system in his hand at the start of the new commercial for Super Bowl LVII. With a snap of ...

We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...

If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that price might actually represent for you. The stock has been under pressure ...